FUSION-TARGET project stems from patented pipeline for gene fusion detection from RNA-sequencing-based approaches and aims to validate it, prove its applicability for diagnostic and therapeutic purposes and its clinical utility in the onco-hematological field. To this aim, the project will investigate the coding and oncogenic capacity of selected fusions, their immunogenic potential and their effect on the immune microenvironment, in order to identify personalized therapeutic strategies (including small molecule and immune checkpoint inhibitors, immune receptors targeting the fusion product and vaccines) and pave the way for their clinical exploitation through the establishment of a shared Molecular Tumor Board (MTB).

FUSION-TARGET has the potential to improve diagnosis and cure of hematological malignancies in the short and long term, providing the rationale for the design of innovative clinical trials in which tailored therapies are assigned, not only on the basis of the mutational landscape, but also on the expressed fusions.

Funding Agency

Ministry of Health

Funding Scheme  

National Recovery and Resilience Plan - Mission 6 - Health

Component

C2 - Innovation

Investment

2.1 Enhancement and strengthening of biomedical research in the NHS

Role

Coordinator

Operative Unit

4

Budget

€1.000.000

Start date

10 May 2023

Duration

24 months

Ultimo aggiornamento: 06 luglio 2025, 16:13

Anche tu puoi fare molto per la lotta ai tumori!

Tu con Noi puoi sostenere la ricerca svolta ogni giorno nei nostri laboratori, puoi far sì che le cure siano sempre più efficaci, che il periodo di terapia sia vissuto più lievemente. I modi per farlo sono tanti.